Seamlessly bridging preclinical screening, chromatographic standardization, GLP toxicology, and Phase I clinical trial materials.
A rigorous examination of contractual investigational medicinal product (IMP) synthesis, First-in-Human (FIH) safety gating, and botanical active standardization.
In the contemporary biopharmaceutical development pipeline, advancing a lead compound or standardized botanical formulation from preclinical validation to human clinical trials represents the most severe risk-adjusted juncture. An OEM Phase I Manufacturer operates at the convergence of micro-scale laboratory discovery and macro-scale industrial manufacturing. Unlike Phase III or commercial-scale toll manufacturing where process validation relies on long steady-state runs, Phase I Contract Development and Manufacturing Organizations (CDMOs) face low-volume, high-complexity production schedules characterized by rigorous investigational drug accountability, evolving physicochemical attributes, and unforgiving regulatory scrutiny.
Under the stewardship of MedGence (Yineng Pharma), Phase I contract manufacturing integrates comprehensive analytical characterization, Good Laboratory Practice (GLP) toxicology backing, and current Good Manufacturing Practice (cGMP) pilot operations. Over 14+ years of dedicated natural medicine research, our enterprise has modernized 83 classical Traditional Chinese Medicine (TCM) formulas, developed 22 innovative natural pharmaceutical entities, secured 56 hospital preparation registrations, and engineered precision quality standards for nearly 400 single-herb active substances. This wealth of empirical formulation intelligence directly addresses common Phase I vulnerabilities: compound instability, unpredictable bioavailability, polymorph variability, and trace impurity escalation.
Whether the target therapeutic candidate is a synthetic small-molecule entity or a multi-component botanical matrix governed by the US FDA Botanical Drug Development Guidance, the operational paradigm must ensure uncompromising patient safety in Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts. MedGence's integrated CRO-CDMO framework bridges raw material origin potency profiling directly into cleanroom encapsulation, clinical labeling, serialization, and double-blind placebo generation.
Precision pilot manufacturing of clinical dosage forms—tablets, specialized dual-chamber oral liquids, softgels, micro-granules, and lyophilized active powders—under validated Class D to Class B cleanroom standards.
Comprehensive solubility profiling, salt selection, excipient compatibility screening, and gastrointestinal permeability assays (Caco-2 models) designed to guarantee reproducible in vivo pharmacokinetic absorption.
Indistinguishable physical characteristics for clinical blinding: exact organoleptic, colorimetric, density, and aromatic emulation of complex botanical and synthetic active medicines without pharmacological cross-talk.
How specialized OEM Phase I manufacturers adapt manufacturing protocols to patient demographics, regional regulatory standards, and therapeutic delivery routes.
Rapid iterative batch production of escalating strength dosages. Micro-runs of 500 to 5,000 units are manufactured, tested, and released under Accelerated Stability Protocols (ICH Q1A) within dynamic 14-day turnaround cycles between escalating clinical dose cohorts.
Fulfilling the complex multi-target requirements of the US FDA Botanical Drug Guidance. We standardize batches using High-Performance Thin-Layer Chromatography (HPTLC) fingerprinting and HPLC-MS multi-component profiling, guaranteeing batch-to-batch chemical consistency.
Leveraging China's progressive clinical regulatory framework where verified hospital preparations (developed across our 56 institutional registrations) are transformed into industrialized Phase I candidate drugs with established human observational safety profiles.
Executing comparative pharmacokinetic and pharmacodynamic BE testing for international formulations entering the Chinese National Medical Products Administration (NMPA) approval pathway or global generic conversions seeking EU/FDA clearance.
Merging artificial intelligence, continuous micro-processing, and multi-omic analytical platforms into early-phase drug product engineering.
Integrating machine learning models trained on hundreds of thousands of historical botanical extraction batches. Predictive algorithms model solubility profiles, thermodynamic stability, and degradation pathways before raw material comminution, shrinking formulation lead-times by up to 60%.
Transitioning from static bulk maceration to continuous supercritical CO2 and microfluidic multi-stage separation. This technology achieves atomic-level purity controls for thermolabile secondary metabolites, preventing oxidation of active flavonoids, iridoids, and terpenes.
Employing Process Analytical Technology (PAT) incorporating in-line Near-Infrared (NIR) and Raman spectroscopy. Phase I batches are evaluated continuously during mixing, granulation, and compression, providing empirical assurance of critical quality attributes (CQAs).
The roadmap for high-potency Phase I clinical supply centers on eliminating the translation barrier between raw agronomic materials and sterile, patient-ready dose administration. Traditional pharmaceutical manufacturers frequently incur massive capital delays attempting to force multi-component active ingredients through synthetic batch machinery. MedGence’s continuous improvement timeline focuses on three distinct vectors: (1) Green Chemistry Purification, minimizing organic solvents through membrane cascade distillation; (2) Intelligent Formulation Vectors, implementing lipid nanoparticles (LNPs) and cyclodextrin inclusion complexes for hydrophobic phytochemicals; and (3) Fully Digitized e-Batch Records (EBR) conforming strictly with 21 CFR Part 11 for real-time remote client audits.
Unlocking early-phase drug development acceleration via centralized botanical biodiversity, deep talent density, and integrated clinical hospital clusters.
Situated in Hunan, a central biodiverse botanical center of China, our operations interface directly with Good Agricultural and Collection Practices (GACP) wildcrafting and cultivation belts. We track active compound variations across micro-climates, altitude gradients, and harvest intervals with high analytical granularity.
Where Western early-phase contract synthesis typically faces 9–14 month backlogs for specialty pilot suites, MedGence leverages integrated pilot plants and internal analytical development pipelines to deliver release-tested, stability-initiated Phase I clinical supplies within 12–16 weeks post-protocol sign-off.
Longstanding technical integration with premier medical institutions—such as Xiangya Hospital, Shanghai Shuguang Hospital, and the First Hospital of Hunan University of Chinese Medicine—enables frictionless protocol review, rapid Institutional Review Board (IRB) clearance, and expedited patient recruitment.
Ensuring investigational medicinal products effortlessly satisfy FDA, EMA, and NMPA investigational new drug filing requirements.
The manufacturing of Phase I investigational clinical products is heavily scrutinized by regulatory authorities worldwide. While early clinical batches benefit from phase-appropriate GMP flexibility, patient safety requirements remain non-negotiable. MedGence maintains an uncompromising Quality Management System (QMS) aligned with ICH Q7, ICH Q10, and 21 CFR Part 211.
Every clinical batch produced in our facilities is accompanied by an audit-ready Chemistry, Manufacturing, and Controls (CMC) technical dossier. Our scientific leadership conducts comprehensive method validation following ICH Q2(R1), documenting specificity, linearity, range, precision (repeatability and intermediate precision), detection limit (LOD), quantitation limit (LOQ), and system suitability across high-performance thin-layer chromatography (HPTLC), HPLC with photodiode array (PDA), refractive index (RID), or mass spectrometry (MS) detection, and gas chromatography (GC) for volatile components and residual solvents.
In-house GLP toxicology pipelines: LD50 determination, acute systemic toxicity, sub-chronic toxicity, and genotoxicity batteries (Ames test, in vitro chromosomal aberration, and in vivo micronucleus assays).
Inductively Coupled Plasma Mass Spectrometry (ICP-MS) and GC-MS/MS screening for 500+ organochlorine, organophosphate, and pyrethroid pesticide residues, ensuring compliance with Ph. Eur. 2.8.13 and USP <561>.
Dedicated cleanrooms with separate HVAC air handling, strictly compartmentalized electronic access control, and complete non-disclosure governance to ensure client proprietary molecular formulations remain confidential.
A structured stage-gate development trajectory designed for risk minimization and regulatory alignment.
Botanical screening, geographic chemical benchmarking, and active compound verification.
HPLC, GC, and HPTLC fingerprint development, linearity validation, and purity profiling.
Solubility optimization, polymorph evaluation, and critical process parameter (CPP) definition.
Acute and sub-chronic toxicity assays, LD50 validation, and safety margin indexing in vivo.
Clinical batch pilot production, active and matching placebo compounding, and cleanroom encapsulation.
CMC dossier completion, stability initiation (ICH Q1A), randomized blinding, and hospital supply.
In-depth responses for biopharma procurement managers, regulatory affairs executives, and clinical directors.
An OEM Phase I Manufacturer specializes in early-stage, agile clinical batch manufacturing (typically 500 to 20,000 dosage units) governed by phase-appropriate GMP. Rather than focusing on high-speed continuous line efficiency, Phase I manufacturers excel at pre-formulation adaptation, rapid analytical method establishment, active and matching-placebo production, randomized kit packaging, and generating complete CMC technical packages for IND (Investigational New Drug) submissions.
Unlike synthetic single-molecules, botanical drugs contain complex arrays of phytochemical compounds. We establish chromatographic fingerprints using high-performance thin-layer chromatography (HPTLC), HPLC-DAD/MS, and GC-FID/MS. We cross-reference multi-origin raw materials across diverse seasons and plant tissues, standardizing active markers (such as specific saponins, flavonoids, or alkaloids) to maintain similarity scores above 0.95 across successive clinical lots, fully satisfying FDA and EMA botanical consistency standards.
Yes. Our flexible pilot suites are configured for micro-campaign manufacturing. As trial safety committees analyze cohort data from initial Single Ascending Dose (SAD) cohorts, our production and analytical release teams can compound, encapsulate, inspect, and release the next higher dosage tier within 10 to 14 days, supported by concurrent accelerated stability testing under ICH Q1A guidelines.
We operate exclusively under an entrusted contract research and manufacturing paradigm. Complete legal assignment of all developed analytical protocols, synthesis parameters, and batch data is transferred to the sponsor. Our facilities utilize segregated air handling units (AHU), restricted physical and electronic access controls, encrypted offline data storage, and strict non-disclosure obligations across all scientific personnel.
Our cGMP pilot facilities support an expansive variety of clinical delivery systems, including hard gelatin and vegetarian HPMC capsules (powder-filled, granule-filled, or liquid-filled), direct-compression and wet-granulation tablets, functional oral liquids and elixirs, micro-granules for oral suspension, concentrated liquid extracts, and sterile topical formulations.
Yes. We provide complete Chemistry, Manufacturing, and Controls (CMC) documentation conforming to Module 3 of the Common Technical Document (CTD). This includes full validation reports for analytical methods, degradation profile characterizations, batch analysis data, certificate of analysis (CoA), stability testing results, and toxicological safety documentation for regulatory review by the US FDA, EMA, or China NMPA.
Select your operational track below to request formal analytical validation scopes, batch manufacturing lead times, and regulatory CMC audit packages.
